In contrast, treatment of ASMC of COPD patients with miR-101-3p inhibitors upregulated MTCO2 expression in a concentration-dependent manner (Figures 2(a) and 2(b)). The gene discussed is MT-CO2; the disease is chronic obstructive pulmonary disease.